Foundation One has announced that The Food and Drug Administration (FDA) has approved a “breakthrough device” that has the potential to match cancer patients with more accurate individualized treatment regiments with just one test. This test will push the boundaries of personalized medicine as it might allow us to choose better treatments that are most likely to be effective for specific types of cancer — and to make those decisions sooner.
CHMP has recommended that Zytiga be approved for earlier use.
Xgeva (Denosumab) is not for men with Advanced Prostate Cancer who do not have identifiable bone metastases.
An application has been made to the FDA for apalutamide, a possible hormonal treatment for men who are castrate resistant, but not yet metastatic.
Recent research has concluded that for men who are going to use early chemotherapy along with hormone therapy, chemotherapy should be delayed, allowing at least three weeks to pass after starting the hormone therapy before commencing the chemotherapy treatments.
The FDA has been asked to expand Zytiga's label to allow its use to treat men with earlier stages of metastatic prostate cancer.
It was announced that Enzalutamide (Xtandi) is the first androgen receptor-inhibitor to demonstrate a statistically significant improvement in metastasis-free survival (MFS) in men who have castrate resistant prostate cancer but do not have any confirmed metastases.
Becoming castrate resistant is a significant turn of events for men with advanced prostate cancer. Before you accept this new diagnosis make sure that you confirm its validity.
Getting Provenge is a two step process, understanding what to expect will make your experience easier. You will also need to make some decisions about how you want to get it.
A study released at the 2010 ASCO meeting showed that denosamab(Xgeva) is superior to zoladronic acid (Zometa).
Looking forward to a new drug that will directly compete with Xtandi (enzaludamide).
Two game changing trials demonstrated that the early use of Zytiga along with hormone therapy (ADT) can provide a significant survival advantage for men with aggressive, hormone naive prostate cancer. The data is very clear for men with metastatic disease, but there remains some controversy if this holds up for men who are not metastatic.
Analyses showed that there is a statistically significant survival advantages for men who had a low baseline testosterone level prior to starting ADT.
A Man’s quality of Life is directly related to how long he will survive. So, why don't we have more resources available to help improve our QoL?
Zytiga (abiraterone acetate) is now available in a new dosage and a new formulation. Zytiga can now be dispensed in tablets that are 500 mg instead of 250 mg and these new 500 mg tabs are film coated.
In a prospective, real-world analysis, it was shown that African American men, who have castrate resistant, metastatic prostate cancer, benefited receiving an additional overall survival (OS) benefit when they received Sipuleucel-T (Provenge).